For decades, mesothelioma treatment moved slowly. The combination of pemetrexed and cisplatin was the FDA-approved first-line standard from 2004 onward, and most families heard the same regimen from every oncologist for nearly two decades.
That has changed in three concrete steps over the past five years.
This page is the practical map: what’s actually FDA-approved as of 2026, what’s in late-stage trials, and what families should ask their treatment team about. Every numerical claim and trial name on this page is sourced from FDA approvals, peer-reviewed publications, or NCI-recognized registries. Where evidence is incomplete or conflicted, this page says so.
What’s FDA-approved as of 2026
Pemetrexed + platinum chemotherapy (the long-standing first-line backbone)
The combination of pemetrexed with cisplatin (or carboplatin in patients who can’t tolerate cisplatin) has been the FDA-approved first-line chemotherapy for mesothelioma since 2004. It remains a standard option, particularly for patients who aren’t candidates for immunotherapy (for example, people with autoimmune conditions or organ transplant history).
The MAPS Phase III trial (IFCT-GFPC-0701, 448 patients, French Cooperative Thoracic Intergroup) showed that adding bevacizumab (Avastin) to pemetrexed + cisplatin extended median overall survival from 16.1 months to 18.8 months, with a manageable increase in side effects (mainly hypertension and thrombosis). Bevacizumab is not formally FDA-approved for mesothelioma, but the addition is supported by Phase III data and recognized in clinical practice for eligible patients.
Tumor Treating Fields (NovoTTF-100L / Optune Lua)
The FDA approved the NovoTTF-100L System (now marketed as Optune Lua) on May 23, 2019, under the Humanitarian Device Exemption (HDE) pathway, for use with pemetrexed and platinum-based chemotherapy in adults with unresectable, locally advanced or metastatic malignant pleural mesothelioma.
The device is a non-invasive, wearable system that delivers low-intensity electric fields (“Tumor Treating Fields”) through electrode arrays placed on the chest. The basis for FDA clearance was the STELLAR registration trial — an 80-patient, single-arm, prospective Phase 2 study. Patients receiving Tumor Treating Fields plus chemotherapy had a median overall survival of 18.2 months versus 12.1 months in a historical chemotherapy-only control. There was no increase in serious systemic side effects when the device was added to chemotherapy; mild-to-moderate skin irritation under the electrode arrays was the main device-related toxicity.
What families ask most: the device replaces neither chemotherapy nor immunotherapy — it is added to chemotherapy. Patients wear it 18 or more hours per day, which is a meaningful lifestyle change. Insurance coverage varies; Novocure’s patient access team handles prior-authorization paperwork.
Nivolumab + ipilimumab (Opdivo + Yervoy)
On October 2, 2020, the FDA approved the immunotherapy combination of nivolumab and ipilimumab for first-line treatment of adults with unresectable malignant pleural mesothelioma. This was the first new first-line drug treatment for the disease since pemetrexed in 2004.
The approval was based on the CheckMate-743 trial — an open-label Phase III study (605 patients: 303 randomized to nivolumab + ipilimumab, 302 to platinum + pemetrexed chemotherapy). Median overall survival was 18.1 months in the immunotherapy arm versus 14.1 months in the chemotherapy arm.
The benefit was largest in the non-epithelioid histology subtypes (sarcomatoid and biphasic), where median survival improved from 8.8 months on chemotherapy to 18.1 months on immunotherapy. In the epithelioid subtype, the difference was smaller: 18.7 versus 16.5 months. With long-term follow-up reported in 2025, the 5-year overall survival rate was 14% in the immunotherapy arm versus 6% with chemotherapy.
Practical points: the combination is given as IV infusions on a recurring schedule. Side effects can include fatigue, skin reactions, diarrhea, and immune-related adverse events that need monitoring. It is widely available — most National Cancer Institute–designated cancer centers and many community oncology programs offer it. It is not a cure, but for many patients (especially with non-epithelioid histology) it is a meaningful extension of survival.
Pembrolizumab (Keytruda) + pemetrexed and platinum chemotherapy
On September 17, 2024, the FDA approved pembrolizumab in combination with pemetrexed and platinum chemotherapy as first-line treatment for adults with unresectable advanced or metastatic malignant pleural mesothelioma. This is the most recent FDA approval in mesothelioma as of 2026.
The approval was based on the IND.227 / KEYNOTE-483 Phase 2/3 trial run by the Canadian Cancer Trials Group, the National Cancer Institute Naples, and the IFCT, across hospitals in Canada, Italy, and France. Median overall survival was 17.3 months with pembrolizumab plus chemotherapy versus 16.1 months with chemotherapy alone (hazard ratio 0.79). The confirmed objective response rate was 52% versus 29%.
The combination is now an alternative first-line option to nivolumab + ipilimumab, particularly for patients who may not tolerate dual checkpoint inhibition or whose oncology team prefers the chemotherapy-anchored approach.
What’s in late-stage trials (and what hasn’t worked out)
This section is shorter than families often expect. Many treatments that look promising in early trials don’t pan out at Phase III scale. The honest map of what’s currently in late-stage development:
Therapeutic cancer vaccines: mixed-to-negative recent Phase III evidence
A “therapeutic” cancer vaccine is given to people who already have cancer to teach the immune system to recognize the tumor. For mesothelioma, the largest randomized trial of this approach was DENIM — a multicenter Phase 2/3 study (Belgium, France, Netherlands) testing MesoPher (a dendritic-cell vaccine loaded with allogeneic tumor cell lysate) as maintenance therapy after first-line chemotherapy. Results were published in The Lancet Oncology in 2024 and showed no overall survival benefit versus best supportive care alone. The investigators concluded that any future studies should test the vaccine in combination with checkpoint immunotherapy rather than as standalone maintenance.
CRS-207 (a live-attenuated Listeria monocytogenes vaccine engineered to express mesothelin) has been studied in Phase I trials with chemotherapy and in a Phase II study with pembrolizumab. As of 2026, it is not FDA-approved and remains investigational.
What this means for families: therapeutic vaccines for mesothelioma are not currently a recommended option outside of clinical trial enrollment. Phase III evidence has not supported their use as standalone therapy.
Mesothelin-targeted CAR-T and engineered T-cell therapies
Several Phase I trials are testing engineered T-cell therapies that target mesothelin (a protein highly expressed on most mesothelioma tumors). These are very early in development. As of 2026, no mesothelin-targeted CAR-T product is FDA-approved or close to approval for mesothelioma. Families considering trial enrollment should discuss with their treatment team and verify status on clinicaltrials.gov.
Earlier-detection biomarkers and breath tests
Catching mesothelioma earlier — before symptoms drive a CT scan — would change outcomes more than any drug currently in development. The current state of evidence:
- SMRP / MESOMARK (soluble mesothelin-related peptide blood test) is FDA-cleared as a monitoring tool for patients already diagnosed with mesothelioma. It is not FDA-validated as a screening test for asymptomatic asbestos-exposed populations.
- Breath-based diagnostics — research groups in Europe and the U.S. have published distinguishing-mesothelioma signatures in exhaled breath. As of 2026 none is FDA-cleared, and routine breath-test screening is not a current standard of care.
What this means for high-exposure families (Navy shipyard veterans, occupational asbestos workers, household secondary exposure): if a clinical trial offers screening with biomarker or imaging endpoints, asking about it is reasonable. Routine screening of asbestos-exposed individuals outside of a trial is not currently a covered standard of care.
Treatment innovation by mesothelioma type
Pleural mesothelioma (most common)
The 2020+ approvals — nivolumab + ipilimumab (2020), pembrolizumab + chemotherapy (2024), and NovoTTF-100L + chemotherapy (2019) — primarily apply here. Active research is concentrated on combinations and on biomarker-driven patient selection.
Peritoneal mesothelioma
Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has been the durable advance for peritoneal mesothelioma. Outcomes at experienced peritoneal surface malignancy centers can be substantially better than outcomes for pleural mesothelioma in similarly-staged disease, particularly for the epithelioid subtype. Peritoneal-specific immunotherapy trials are emerging but remain in early phases.
Pericardial mesothelioma (rare) and testicular mesothelioma (very rare)
Both subtypes are too rare for dedicated Phase III trials. Treatment is generally extrapolated from pleural mesothelioma standards, often through expanded-access or off-label use of pleural-mesothelioma-approved drugs.
How families should think about treatment innovations
A frank conversation many oncologists should have with families but often skip:
1. “Innovation” is not a guarantee of better outcomes. A new treatment is meaningful when a randomized Phase III trial shows it extends survival or improves quality of life with acceptable side effects. The FDA-approved combinations on this page (nivolumab + ipilimumab, pembrolizumab + chemo, NovoTTF-100L) have cleared that bar. Several promising-looking Phase II treatments — including the dendritic-cell vaccine maintenance approach — have NOT cleared it.
2. The biggest predictor of outcomes is access to a high-volume mesothelioma center. Treatment outcomes correlate with how many mesothelioma cases a center treats per year. A surgeon who has performed 200+ pleurectomy-decortications operates differently from one who has performed 5. The same is true for medical oncology, radiation oncology, and pathology review (mesothelioma diagnosis can be revised on second pathology opinion).
3. Clinical trials are not “experiments on people.” Modern mesothelioma trials are highly regulated, and patients receive at minimum the current standard of care. No patient is randomized to placebo when an approved treatment exists. Trials are how new options become available. If your treating oncologist is not familiar with currently-open trials, asking for a second opinion at a mesothelioma center is reasonable.
4. Insurance and the VA cover most FDA-approved treatments. The 2019, 2020, and 2024 FDA approvals are covered by Medicare, Medicaid, the VA, and most commercial insurance. Coverage of trials varies — the trial sponsor typically covers experimental drugs and trial-specific monitoring, while insurance covers standard-of-care portions. Patient access teams at major centers help families navigate this.
5. Travel for treatment is sometimes the right call. Many families travel from rural areas to NCI-designated cancer centers for surgery or for trial enrollment. The Mesothelioma Applied Research Foundation maintains a list of high-volume centers. Travel grants exist for veterans and for patients meeting income criteria.
Questions to ask your treatment team
- Based on my mesothelioma type, stage, histology, and overall health, am I eligible for first-line nivolumab + ipilimumab, pembrolizumab + chemotherapy, NovoTTF-100L + chemotherapy, chemotherapy alone, or a combination?
- If I am eligible for surgery (pleurectomy-decortication, extrapleural pneumonectomy, or cytoreduction + HIPEC for peritoneal disease), how many of these does our team perform per year? Should I seek a second opinion at a higher-volume center?
- What does my pathology actually say — epithelioid, sarcomatoid, biphasic? This affects which treatment is likely to help most.
- Am I eligible for any currently open clinical trials? If yes, which centers run them?
- What is the realistic survival range for someone in my situation, with and without each treatment option?
- What side effects should I watch for, and which require an immediate call to the team versus the next appointment?
- If I cannot tolerate first-line treatment, what are the second-line options?
- How is treatment progress monitored — what scans and what timing — and what does “treatment not working” look like clinically?
- Who on the team coordinates between the oncologist, surgeon, radiologist, pathologist, and palliative care?
What MesoCare does not recommend
This page is not a sales pitch for any specific treatment, center, or trial. We do not refer patients to specific clinics for compensation. Some warnings worth knowing:
- “Alternative” mesothelioma cures (high-dose vitamin C, ozone therapy, off-shore stem cell, untested herbal protocols) have no Phase III evidence of efficacy and are sometimes used by clinics that charge cash up-front. Verify any offered treatment is FDA-approved or registered on clinicaltrials.gov.
- “Free” treatment programs that require sharing your medical records with marketing intermediaries — read what you’re signing.
- Specialists who guarantee outcomes — no honest mesothelioma physician guarantees a specific survival outcome. Ranges, yes. Guarantees, no.
Where to get help next
- Find a high-volume mesothelioma center near you: Mesothelioma Applied Research Foundation maintains a center directory.
- Search active trials: clinicaltrials.gov, search “mesothelioma” + your location.
- Verify a treatment claim: FDA Drugs@FDA database, NCI PDQ for Malignant Mesothelioma Treatment.
- Patient and family support: Asbestos Disease Awareness Organization (ADAO), Mesothelioma Applied Research Foundation patient services.
- Caregiver guidance on this site: The First 30 Days as a Mesothelioma Caregiver: A Practical Guide and The First 30 Days: A Caregiver’s Checklist.
- Specialist selection guidance: How to Choose a Mesothelioma Specialist: 7 Questions to Ask.
- Telehealth and second opinions: Telehealth & Mesothelioma: Getting an Expert Second Opinion from Home.
Sources for this page
Each numerical claim and trial name on this page is grounded in one or more of the following primary sources. Last verified 2026-05-06.
- Pemetrexed + cisplatin (FDA approval 2004) — referenced in the FDA Approval Summary for nivolumab + ipilimumab (PMC8810571), which notes that no drug had received US FDA approval for unresectable mesothelioma since pemetrexed + cisplatin in 2004.
- MAPS Phase III trial (bevacizumab + pemetrexed + cisplatin) — Zalcman G, et al. The Lancet 2016. PubMed 26719230. NCT00651456 (IFCT-GFPC-0701). 448 patients. Median OS 18.8 vs 16.1 months (HR 0.77, p=0.0167).
- NovoTTF-100L FDA HDE approval — FDA HDE H180002, approval order issued May 23, 2019. FDA Summary of Safety and Probable Benefit (accessdata.fda.gov, H180002B). Marketed as Optune Lua™ in the U.S.
- STELLAR Phase 2 registration trial — 80-patient single-arm trial. Median OS 18.2 months (95% CI 12.1–25.8), median PFS 7.6 months. Historical control 12.1 months. Published in The Lancet Oncology.
- CheckMate-743 (nivolumab + ipilimumab) — Baas P, et al. The Lancet 2021 (PMID 33485464; The Lancet S0140-6736(20)32714-8). FDA approval October 2, 2020 (FDA Approval Summary, PMC8810571). 605 patients (303 vs 302). Median OS 18.1 vs 14.1 months. Non-epithelioid 18.1 vs 8.8; epithelioid 18.7 vs 16.5. 5-year OS 14% vs 6% (Journal of Clinical Oncology, JCO-25-01328).
- IND.227 / KEYNOTE-483 (pembrolizumab + chemotherapy) — Phase 2/3 multicenter trial (Canada, Italy, France). FDA approval September 17, 2024. Median OS 17.3 vs 16.1 months (HR 0.79). Confirmed ORR 52% vs 29%. Published in The Lancet 2023 (PMID 37931632).
- DENIM trial (MesoPher dendritic-cell vaccine) — multicenter Phase 2/3, Belgium/France/Netherlands. Published in The Lancet Oncology 2024 (PMID 38848742). Dendritic cells loaded with allogeneic tumour cell lysate as maintenance after chemotherapy did NOT improve overall survival vs best supportive care alone.
- CRS-207 (anti-mesothelin Listeria vaccine) — Phase I (PMID 22147941) and combined-modality Phase II studies (PMID 31263030). Phase II with pembrolizumab in MPM. Not FDA-approved as of 2026.
- SMRP / MESOMARK biomarker — FDA-cleared as a monitoring assay for known mesothelioma; not validated for screening asymptomatic populations.
- NCI PDQ: Malignant Mesothelioma Treatment (Health Professional version) at cancer.gov — for general treatment landscape and standard-of-care references.